Surgical Treatment of Chronic Periprosthetic Joint Infection: Fate of Spacer Exchanges

Running Title: Fate of Spacer Exchanges in PJI

Timothy L. Tan MD
Karan Goswami MD
Michael M. Kheir MD
Chi Xu MD
Qiaojie Wang MD
Javad Parvizi MD FRCS

1 Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA
2 Indiana University School of Medicine, Indianapolis, IN
3 Shanghai Jiao Tong University, Shanghai, China

Corresponding Author
Javad Parvizi MD, FRCS
Rothman Orthopaedic Institute
125 S 9th St, Ste 1000
Philadelphia, PA 19107
P: 267-339-7813
F: 215-503-5651
parvi@aol.com

This is the author's manuscript of the article published in final edited form as:
Surgical Treatment of Chronic Periprosthetic Joint Infection: Fate of Spacer Exchanges

Running Title: Fate of Spacer Exchanges in PJI
ABSTRACT

Introduction: Patients with periprosthetic joint infection (PJI) undergoing two-stage exchange arthroplasty may undergo an interim spacer exchange for a variety of reasons including mechanical failure of spacer or persistence of infection. The objective of this study was to understand the risk factors and outcomes of patients that undergo spacer exchange during the course of a planned two-stage exchange arthroplasty.

Methods: Our institutional database was used to identify 533 patients who underwent a two-stage exchange arthroplasty for PJI, including 90 patients with a spacer exchange, from 2000-2017. A retrospective review was performed to extract relevant clinical information. Treatment outcomes included 1) progression to reimplantation and 2) treatment success as defined by a Delphi-based criterion. Both univariate and multivariate COX regression models were performed to investigate whether spacer exchange was associated with failure. Additionally, a propensity score analysis was performed based on a 1:2 match.

Results: A spacer exchange was required in 16.9%. Patients who underwent spacer exchanges had a higher body mass index (BMI) (p<0.001), rheumatoid arthritis (p=0.018), and were more likely to have PJI caused by resistant (0.048) and polymicrobial organisms (p=0.007). Patients undergoing a spacer exchange demonstrated lower survivorship and an increased risk of failure in the multivariate and propensity score matched analysis compared to patients who did not require a spacer exchange.

Discussion: Despite an additional load of local antibiotics and repeat debridement, patients who underwent a spacer exchange demonstrated poor outcomes, including failure to undergo reimplantation and twice the failure rate. The findings of this study may need to be borne in mind when managing patients who require spacer exchange.
Keywords: Periprosthetic Joint infection, knee, hip, infection, spacer exchange, two-stage exchange
INTRODUCTION

Treatment of periprosthetic joint infection (PJI) after total joint arthroplasty (TJA) remains a challenge with a high failure rate[1,2]. Two-stage exchange arthroplasty is the most frequent treatment for chronic PJI, involving removal of the components and insertion of an antibiotic impregnated cement spacer in the first stage and reimplantation of permanent implants at a later stage [3,4]. Outcomes after two stage exchange arthroplasty remain far from perfect as many patients are not ultimately reimplanted and multiple surgeries are frequently required to eradicate infection[2,5,6].

There are occasions when the initial antibiotic cement spacer may be exchanged, which is termed by some as the “three stage exchange” as it involves an additional surgical procedure. Reasons for a spacer exchange may include persistent infection or a fractured or dislocated spacer [2,7,8]. In patients with persistent infection, the rationale behind a spacer exchange is to deliver an additional load of local antibiotics and to repeat surgical debridement to treat the persistent infection.[9–11] Although this practice has been adopted by some surgeons, there is minimal literature on the outcomes of spacer exchange. Understanding the outcomes of spacer exchanges is important as a spacer exchange further delays reimplantation and subjects the patient to an additional surgery and all the morbidities associated with it.

The aim of this study was to report the prevalence, characteristics and outcomes of patients with PJI who required a spacer exchange during the course of their intended two-stage exchange arthroplasty. We also intended to compare the outcome of these patients with those undergoing conventional two-stage revision without an interim spacer exchange.
MATERIALS AND METHODS

A retrospective institutional study was performed to identify all patients with PJI who underwent a two-stage exchange arthroplasty from January 2000 to May 2017. The diagnosis of PJI was based on the Musculoskeletal Infection Society (MSIS) and the International Consensus Meeting criteria[12,13]. Patients with a megaprostheses, initial infection with a fungal organism, prior native septic arthritis, or prior failed two-stage exchange arthroplasty were excluded. We also excluded 80 patients with reimplantation due to follow-up less than 1 year after reimplantation and 18 patients without eventual reimplantation by May 2018 due to lost to follow-up after the last spacer insertion. After the aforementioned criteria, 533 joints (203 hips and 330 knees) were included in the final analysis. Of these 533 joints, 90 patients (31 hips and 59 knees) underwent an initial interim spacer exchange during the course of their two-stage revision treatment (exchange group). This cohort was compared with a control group of 443 PJs (172 hips and 271 knees) that did not undergo an interim spacer exchange (Figure 1).

A retrospective review was performed to extract relevant information regarding surgical treatment, microbiology during resection arthroplasty, demographic data (age, body mass index [BMI], gender), Charlson comorbidity index (CCI) [15], diabetes, rheumatoid arthritis, index surgery (primary or revision), prior irrigation and debridement (I&D) on the same joint, the presence of a sinus tract, follow-up time, date of surgery, and antibiotics used in the spacer. Both static (66.8%) and articulating spacers (33.2%) were utilized containing dual antibiotics against both gram positive and gram-negative organisms; 1 to 3 g of vancomycin and 1 to 3.6 g of tobramycin per 40-gram pack of bone cement was used almost exclusively (98.3%). The articulating spacers were intraoperatively constructed primarily from prefabricated molds with endoskeleton implants. The decision to undergo reimplantation was based on trending of serum
inflammatory markers and a healing wound. Routine aspiration prior to reimplantation was not performed. In patients in whom there was suspicion of continued infection, such as poor wound healing, intraoperative purulence, or mechanical spacer issues, it was institutional protocol for a repeat spacer to be performed in order to introduce a new load of antibiotics. The decision to perform multiple spacers exchanges rather than undergo salvage surgery with a girdlestone, or fusion was based on a shared decision between the patient and surgeon. Following reimplantation, patients were routinely suppressed with antibiotics starting in 2016.

The primary endpoints of this study were 1) failure to ultimately undergo reimplantation, and 2) treatment failure after reimplantation as assessed by the Delphi method-based criteria by Diaz-Ledezma [7]. The latter endpoint was defined as: 1) failed infection eradication, characterized by the presence of a sinus tract, drainage, pain, or infection recurrence caused by the same organism strain; 2) subsequent surgical intervention for infection after reimplantation surgery; or 3) occurrence of PJJ-related mortality[16]. Patients on suppression were not considered a failure. Failure was only evaluated after reimplantation to ensure that the starting point was the same for both groups and to comply with the aforementioned definition of success.

Statistical Analysis

All of the statistical analyses were performed with the statistical software package R (http://www.R-project.org, The R Foundation). The clinical characteristics between groups were compared with the use of the independent t-test or Mann-Whitney test for continuous variables and the chi-square test or Fisher’s exact test for categorical variables. Kaplan-Meier survivorship curves were generated to compare outcomes and a log-rank test was performed to assess statistical significance. Both univariate and multivariate logistic regression models were performed to investigate whether spacer exchange was associated with failure to reimplantation.
and Cox regression models were conducted to identify the relationship between spacer exchange and treatment failure. In the multivariate model, we adjusted all variables included in Table 1. Results were presented as odds ratios (OR) or hazards ratio (HR) with 95% confidence intervals (CI).

Sensitivity Analysis

A set of sensitivity analysis was performed using propensity score matching (PSM), which can adjust for some baseline group differences and is a well-accepted method to account for identified confounding variables [17,18]. Propensity scores of spacer exchange (vs. no spacer exchange) were estimated by logistic regression using age, gender, BMI, joints, CCI score, index surgery, diabetes, rheumatoid arthritis, the present of a sinus tract, prior I&D on the same joint, resistant organisms (Methicillin Resistant Staphylococcus Aureus (MRSA) or Vancomycin Resistant Enterococcus (VRE)), polymicrobial organisms, and duration of follow-up. Patients who underwent a spacer exchange were matched 1:2 (without a spacer exchange) on the logit of the propensity score using a nearest-neighbor matching approach. The maximum difference between propensity probabilities for matching was set at 0.2. A standardized mean difference (SMD) for each covariate was used to examine the balance of covariates between patients who received a spacer exchange and matched control individuals. PSM score was adjusted in the multivariate model. For all statistical analyses, significance was set at an alpha of 0.05.

RESULTS

Patient demographics and culture results at the initial spacer implantation are shown in Table 1. One or more spacer exchanges were required in 16.9% of two stage exchange arthroplasties (90/533). Patients in the spacer exchange group had a higher mean body mass
index (BMI) (34.4 ± 8.5 vs. 31.4 ± 8.0 kg/m^2, p<0.001) and percentage of rheumatoid arthritis (14.6% vs. 7.0%, p=0.018) compared to the control group. *S. aureus* was the predominant organism in both the spacer exchange and the control group (36.7% vs. 39.3%, p=0.643). The prevalence of PJI caused by resistant organisms (23.3% vs. 14.9%, p=0.048) and polymicrobial organisms (18.9% vs. 9.3%, p=0.007) were significantly higher in the spacer exchange group compared to controls. Of the patients with persistent infection, the organism was same between the spacer exchange and initial spacer insertion in 11.5% of patients, all of which were antibiotic resistant organisms (MRSA or VRE).

Seventy-nine patients had only 1 spacer exchange (2 spacers total), 8 patients had 2 spacer exchanges (3 spacers total), 2 patients had 3 spacer exchanges (4 spacers total), and 1 patient had 4 spacer exchange (5 spacers total). The reasons for the initial spacer exchange included suspected persistence of infection (74/90), spacer dislocation (7/90), and fracture or unknown reasons (9/90).

Of the 533 intended two stage exchange arthroplasties, the overall reimplantation rate was 79.7% (425/533). The reimplantation rate was 70.0% (63/90) for patients with at least one spacer exchange compared to 81.7% (362/443) for those without spacer exchange. After adjusting all confounders, patients with a spacer exchange were at an increased risk of failure to undergo reimplantation (OR, 1.96; 95% CI, 1.08 to 3.53; **Table 2**). The reasons for not undergoing reimplantation among 27 patients in the spacer exchange group were: medically unfit for reimplantation (n=11), salvage procedures for persistent infection (5 fusion, 3 amputation and 1 girdlestone), death during stages (n=3), and decision to retain spacer either by the patient or the surgeon (n=4).
Following reimplantation, the overall treatment success rate according to the Delphia-based definition was 75.1% (319/425) with a mean follow-up of 5.1 year (range 1.0 to 16.2 years). The reinfection rate was 41.3% (26/63) for patients with spacer exchange compared to 22.1% (80/362) for those without spacer exchange. In patients with a spacer exchange for mechanical failure, the failure rate after reimplantation was 33.33% (4/12) compared to 43.14% (22/51) in patients who underwent an exchange for infection (p = 0.746) and 22.10% (80/362) in those without a reoperation (p=0.479). After adjusting all confounders, the reinfection rate in patients with spacer exchange was significantly higher than controls (HR, 2.05; 95% CI, 1.08 to 3.89; Table 3). Kaplan-Meier survivorship curves also revealed a significantly lower treatment success in the spacer-exchange group compared to controls using log-rank test (p<0.001, Figure 2). The results were similar when isolating only patients that received a spacer exchange for infection; Kaplan-Meier survivorship curve revealed significantly lower treatment success rates in this stratified cohort as compared to controls (p<0.001, Figure 3). When stratified by joint, survivorship was lower in patients with a spacer exchange compared to those without a spacer exchange with treatment failure as an endpoint for both THAs (Figure 4) and TKAs (Figure 5).

Through using propensity score matching (PSM), we generated a subsample of 88 cases with a spacer exchange and 176 matched controls without a spacer exchange. The patient characteristics after matching were shown in Appendix Table 1 and the quality of PSM was considered balanced (all SMD< 0.2). Patients with a spacer exchange did not demonstrate a higher rate of failure to undergo reimplantation in the propensity score analysis (PSM score-adjusted OR, 1.44; 95% CI, 0.80 to 2.60; Table 2). The relationship between spacer exchange and subsequent reinfection remained robust; reinfection rate in patients with spacer exchange was significantly higher than matched controls (PSM score-adjusted HR, 2.23; 95% CI, 1.14 to
Kaplan-Meier survivorship curves revealed a significantly lower treatment success in the spacer-exchange group compared to matched controls (p=0.007, Appendix Figure 1). When isolating only patients that received a spacer exchange for infection, the results did not change (p=0.006, Appendix Figure 2).

DISCUSSION

A spacer exchange for persistent infection or spacer-related mechanical complications such as fracture or dislocation may be performed in patients undergoing two-stage exchange arthroplasty. In the current study, 16.9% of patients who underwent an intended two-stage exchange arthroplasty had an interim spacer exchange. The primary reason of spacer exchange was suspicion of persistent infection. These patients were more likely to have obesity, rheumatoid arthritis, or PJI caused by resistant and/or polymicrobial organisms compared to those without a spacer exchange. Interestingly, spacer exchange was associated with an increased risk of reinfection following reimplantation regardless of whether the exchange was done for mechanical failure of the spacer or suspicion for persistence of infection. These findings continued to be present after the propensity score analysis which matched for baseline differences in comorbidities.

To our knowledge, only one other study has specifically investigated outcomes after spacer exchanges[10]. In a series of 347 two stage exchanges, including 59 spacer exchanges, George et al. found that patients who underwent spacer exchanges had decreased survivorship (p=0.020) after reimplantation[10]. In addition, the spacer exchange group demonstrated increased comorbidities, and an increased prevalence of resistance organisms. Our results are
consistent with the prior study in demonstrating a poor outcome for patients undergoing an
interim spacer exchange.

There are several possibilities that may explain the poor outcome in patients with a spacer
exchange. The most likely reason is that the patients may be poor hosts with increased
comorbidities and/or difficult to eradicate organisms (e.g. resistant or polymicrobial) which may
predispose the patient to persistent infection[19–21]. However, even in the multivariate and
propensity score analysis, patients who underwent a spacer exchange, including those for
mechanical failure of spacer, were more likely to have subsequent treatment failure. Thus, it is
possible that the increased risk of treatment failure in patients undergoing spacer exchange may
be the result of catabolic burden and morbidity that an additional surgery carries. This may be
particularly true in patients with extensive comorbidities. In fact recognizing the issues related to
an additional surgery, the Second International Consensus Meeting on Orthopedic Infections
(ICM) recommends that patients with mechanical failure of a spacer should not undergo an
additional spacer exchange unless the failed spacer results in soft tissue problems[11].
Regardless of the reason for the increased risk of failure and poor outcome, the present study
suggests that the frequent treatment of a persistent infection after a two-stage exchange with an
additional repeat spacer demonstrates poor outcomes and that the utility of this treatment method
should be reconsidered.

Another important issue to examine is that patients who failed after a two-stage exchange
arthroplasty or were suspected of having a persistent infection are more likely to be infected with
more virulent organisms such as Staphylococcal species and/or resistant organisms [5,22,23,24].
We found similar results in this study, with Staphylococcal species comprising the majority of
persistent infections during the first spacer exchange followed closely by other resistant
organisms. While subsequent surgery after failure of a two-stage exchange demonstrate poor outcomes in the literature, we found that patients undergoing spacer exchanges mirror these results with a high rate of salvage procedures.

There are several limitations to this study that should be considered. First, the study is retrospective in nature and thus relies on accurate and detailed documentation. This limitation is particularly important when evaluating the reason for not undergoing reimplantation, as this was infrequently recorded in the medical record. In addition, although clinical signs and improvement are also used as a proxy for infection control, this information is difficult to obtain in a retrospective study. Furthermore, there were differences in baseline characteristics which may result from a selection bias as it is feasible that a surgeon is more aggressive and more likely to perform a spacer exchange in patients with increased comorbidities and/or PJI caused by resistant organisms. However, we attempted to control for these baseline differences using both a multivariate analysis and propensity score matching based analysis. In addition, the influence of antibiotic suppression could not be controlled for as this information was not readily available. Furthermore, while we found that patients that underwent a spacer exchange were more likely to have rheumatoid arthritis, we were unable to investigate the influence of anti-rheumatic medication, including the role of modern disease-modifying antirheumatic drugs, which selectively target the immune system. Additionally, many patients were lost to follow up as many of these patients were referred from an outside hospital and follow-up with their original surgeon whose records are not readily available. This may thus reflect an underestimation of the true failure rate. Lastly, it was routine protocol to perform a spacer exchange rather than a girdlestone at our institution with the intent of introducing more local antibiotics. We acknowledge that there is no clear consensus regarding the optimal management of persistent
infection in the setting of a spacer and that some surgeons will resort to an “implant holiday” prior to an intended reimplantation.

In summary, the present study highlights the challenges that remain in managing patients with persistent infection after an initial spacer implantation. Despite delivery of an additional load of local antibiotics and further debridement, outcome of surgical treatment of these patients remains poor and the risk of failure is actually increased. Furthermore, a significant number of patients with a spacer exchange never ultimately undergo reimplantation despite being subject to the morbidity of another surgery. Surgeons should be cognizant of these suboptimal outcomes after treatment with an additional spacer exchange and alternative strategies are certainly needed. It is crucial for subsequent studies to understand risk factors for subsequent failure of a spacer exchange in order to determine the indications for a spacer exchange.
References:


comorbidity in longitudinal studies: development and validation. Journal of chronic
[17] Kahlert J, Gribsholt SB, Gammelager H, Dekkers OM, Luta G. Control of confounding in
[18] Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of
Evaluation of a Prognostic Calculator for the Surgical Treatment of Periprosthetic Joint
Outcome of Treatment and Identification of Risk Factors. J Bone Joint Surg Am
[21] Marculescu CE, Cantey JR. Polymicrobial Prosthetic Joint Infections: Risk Factors and
treatment of hip periprosthetic joint infection is associated with a high rate of infection
Stage Exchange Have Poor Outcomes After Further Surgical Intervention. J Arthroplasty
### Appendix Table 1 Patient demographics after matching

<table>
<thead>
<tr>
<th></th>
<th>Exchange group (N=88)</th>
<th>Non-exchange group (N=176)</th>
<th>SMD</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year) (mean ± SD)</td>
<td>65.6 ± 10.3</td>
<td>66.4 ± 10.7</td>
<td>0.0777</td>
<td>0.555</td>
</tr>
<tr>
<td>Male (%)</td>
<td>43 (48.9)</td>
<td>97 (55.1%)</td>
<td>0.1253</td>
<td>0.407</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>34.4 ± 8.5</td>
<td>32.9 ± 8.9</td>
<td>0.1712</td>
<td>0.195</td>
</tr>
<tr>
<td>Hip (%)</td>
<td>31 (35.2)</td>
<td>68 (38.6)</td>
<td>0.0707</td>
<td>0.686</td>
</tr>
<tr>
<td>CCI score (mean ± SD)</td>
<td>3.9 ± 1.72</td>
<td>4.1 ± 1.9</td>
<td>0.1545</td>
<td>0.247</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>27 (30.7)</td>
<td>58 (33)</td>
<td>0.0488</td>
<td>0.816</td>
</tr>
<tr>
<td>Rheumatoid arthritis (%)</td>
<td>13 (14.8)</td>
<td>21 (11.9)</td>
<td>0.0836</td>
<td>0.649</td>
</tr>
<tr>
<td>Index revision (%)</td>
<td>30 (34.1)</td>
<td>56 (31.8)</td>
<td>0.0484</td>
<td>0.816</td>
</tr>
<tr>
<td>Prior I&amp;D (%)</td>
<td>24 (27.3)</td>
<td>53 (30.1)</td>
<td>0.0628</td>
<td>0.738</td>
</tr>
<tr>
<td>Sinus tract (%)</td>
<td>25 (28.4)</td>
<td>56 (31.8)</td>
<td>0.0744</td>
<td>0.671</td>
</tr>
<tr>
<td>Resistant organism (%)</td>
<td>21 (23.9)</td>
<td>40 (22.7)</td>
<td>0.0269</td>
<td>0.959</td>
</tr>
<tr>
<td>Polymicrobial (%)</td>
<td>16 (18.2)</td>
<td>31 (17.6)</td>
<td>0.0148</td>
<td>1.000</td>
</tr>
</tbody>
</table>
**Table 1** Patient demographics

<table>
<thead>
<tr>
<th></th>
<th>Exchange group (N=90)</th>
<th>Non-exchange group (N=443)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year) (mean ± SD)</td>
<td>65.5 ± 10.2</td>
<td>66.0 ± 11.4</td>
<td>0.364</td>
</tr>
<tr>
<td>Male (n, %)</td>
<td>44 (49.4%)</td>
<td>222 (51.7%)</td>
<td>0.692</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>34.4 ± 8.5</td>
<td>31.4 ± 8.0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hip (n, %)</td>
<td>31 (34.4%)</td>
<td>172 (38.8%)</td>
<td>0.435</td>
</tr>
<tr>
<td>CCI score (mean ± SD)</td>
<td>3.9 ± 1.7</td>
<td>3.8 ± 1.8</td>
<td>0.842</td>
</tr>
<tr>
<td>Diabetes (n, %)</td>
<td>27 (30.0%)</td>
<td>101 (22.8%)</td>
<td>0.145</td>
</tr>
<tr>
<td>Rheumatoid arthritis (n, %)</td>
<td>13 (14.6%)</td>
<td>30 (7.0%)</td>
<td>0.018</td>
</tr>
<tr>
<td>Index revision (n, %)</td>
<td>30 (33.3%)</td>
<td>108 (24.4%)</td>
<td>0.077</td>
</tr>
<tr>
<td>Prior I&amp;D (n, %)</td>
<td>26 (28.9%)</td>
<td>146 (33.0%)</td>
<td>0.452</td>
</tr>
<tr>
<td>Sinus tract (n, %)</td>
<td>25 (28.1%)</td>
<td>99 (22.3%)</td>
<td>0.242</td>
</tr>
<tr>
<td>Culture at resection arthroplasty (n, %)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>33 (36.7%)</td>
<td>174 (39.3%)</td>
<td>0.643</td>
</tr>
<tr>
<td>CNS*</td>
<td>26 (28.9%)</td>
<td>95 (21.4%)</td>
<td>0.124</td>
</tr>
<tr>
<td>Resistant organism</td>
<td>21 (23.3%)</td>
<td>66 (14.9%)</td>
<td>0.048</td>
</tr>
<tr>
<td><em>Streptococcus spp.</em></td>
<td>10 (11.1%)</td>
<td>55 (12.4%)</td>
<td>0.730</td>
</tr>
<tr>
<td><em>Enterococcus spp.</em></td>
<td>8 (8.9%)</td>
<td>20 (4.5%)</td>
<td>0.115</td>
</tr>
<tr>
<td>Gram-negative organism</td>
<td>14 (15.6%)</td>
<td>51 (11.5%)</td>
<td>0.285</td>
</tr>
<tr>
<td>Polymicrobial organism</td>
<td>17 (18.9%)</td>
<td>41 (9.3%)</td>
<td>0.007</td>
</tr>
<tr>
<td>Culture negative</td>
<td>10 (11.1%)</td>
<td>71 (16.0%)</td>
<td>0.236</td>
</tr>
</tbody>
</table>

*Coagulase negative staphylococcus
Table 2 Univariate and multivariate analysis for failure to undergo reimplantation
* Before matching, all confounders in Table 1 were adjusted; after matching, PSM score were

<table>
<thead>
<tr>
<th></th>
<th>Reimplantation (n, %)</th>
<th>P-value</th>
<th>Non-adjusted OR</th>
<th>P-value</th>
<th>*Adjust OR</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Before matching</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-exchange group</td>
<td>362 (81.7%)</td>
<td>-</td>
<td>Reference</td>
<td>-</td>
<td>Reference</td>
<td>-</td>
</tr>
<tr>
<td>Exchange group</td>
<td>63 (70.0%)</td>
<td>0.012</td>
<td>1.92 (1.15, 3.19)</td>
<td>0.013</td>
<td>1.96 (1.08, 3.53)</td>
<td>0.026</td>
</tr>
<tr>
<td><strong>After matching</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-exchange group</td>
<td>135 (76.7%)</td>
<td>-</td>
<td>Reference</td>
<td>-</td>
<td>Reference</td>
<td>-</td>
</tr>
<tr>
<td>Exchange group</td>
<td>61 (69.3%)</td>
<td>0.196</td>
<td>1.46 (0.82, 2.58)</td>
<td>0.197</td>
<td>1.44 (0.80, 2.60)</td>
<td>0.220</td>
</tr>
</tbody>
</table>
### Table 3: Univariate and multivariate analysis for association between spacer exchange and treatment failure

<table>
<thead>
<tr>
<th></th>
<th>Failure (n, %)</th>
<th>P-value</th>
<th>Non-adjusted HR</th>
<th>P-value</th>
<th>*Adjust HR</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Before matching</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-exchange group</td>
<td>80 (22.1%)</td>
<td>-</td>
<td>Reference</td>
<td>-</td>
<td>Reference</td>
<td>-</td>
</tr>
<tr>
<td>Exchange group</td>
<td>26 (41.3%)</td>
<td>0.001</td>
<td>2.48 (1.42, 4.34)</td>
<td>0.002</td>
<td>2.05 (1.08, 3.89)</td>
<td>0.028</td>
</tr>
<tr>
<td><strong>After matching</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-exchange group</td>
<td>31 (23.0%)</td>
<td>-</td>
<td>Reference</td>
<td>-</td>
<td>Reference</td>
<td>-</td>
</tr>
<tr>
<td>Exchange group</td>
<td>24 (39.3%)</td>
<td>0.018</td>
<td>2.18 (1.13, 4.18)</td>
<td>0.019</td>
<td>2.23 (1.14, 4.40)</td>
<td>0.020</td>
</tr>
</tbody>
</table>

* Before matching, all confounders in Table 1 were adjusted; after matching, PSM score were adjusted.
A Kaplan-Meier survival curve showing the probability of survival over follow-up time for two groups: Spacer exchange 0 and Spacer exchange 1. The y-axis represents the survival probability, ranging from 0.0 to 1.0, and the x-axis represents the follow-up time in years, ranging from 0 to 10.

The curve for Spacer exchange 0 starts higher and remains higher than the curve for Spacer exchange 1 throughout the follow-up period. The p-value for the difference in survival probability between the two groups is 0.00021.

A table below the curve shows the number of patients at risk at each follow-up point:

<table>
<thead>
<tr>
<th>Follow up (year)</th>
<th>Spacer exchange 0</th>
<th>Spacer exchange 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>362</td>
<td>51</td>
</tr>
<tr>
<td>2.5</td>
<td>238</td>
<td>22</td>
</tr>
<tr>
<td>5</td>
<td>135</td>
<td>13</td>
</tr>
<tr>
<td>7.5</td>
<td>52</td>
<td>7</td>
</tr>
<tr>
<td>10</td>
<td>21</td>
<td>4</td>
</tr>
</tbody>
</table>

The graph indicates a significant difference in survival probability between the two groups, with Spacer exchange 0 having a higher survival probability throughout the follow-up period.
A graph showing survival probability over follow-up time. The x-axis represents follow-up time in years (0 to 5), and the y-axis shows survival probability (0.00 to 1.00). Two groups are compared: Spacer exchange (red line) and No (blue line). The p-value is given as 0.033.

A table below the graph displays the number of patients at risk over follow-up time for each group.

<table>
<thead>
<tr>
<th>Follow up (year)</th>
<th>Spacer exchange</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>131</td>
<td>22</td>
</tr>
<tr>
<td>1</td>
<td>109</td>
<td>14</td>
</tr>
<tr>
<td>2</td>
<td>85</td>
<td>9</td>
</tr>
<tr>
<td>3</td>
<td>64</td>
<td>8</td>
</tr>
<tr>
<td>4</td>
<td>49</td>
<td>7</td>
</tr>
<tr>
<td>5</td>
<td>37</td>
<td>5</td>
</tr>
</tbody>
</table>
A graph showing survival probability over follow-up time for different Spacer exchange statuses.

- **Spacer exchange**
  - No
  - Yes

**Survival probability**
- **Follow up (year)**: 0, 1, 2, 3, 4, 5
- **Survival probability**:
  - 1.00
  - 0.75
  - 0.50
  - 0.25
  - 0.00

**p = 0.0015**

**Number at risk**
- **Spacer exchange**
  - No
    - 231
    - 201
    - 179
    - 147
    - 123
    - 98
  - Yes
    - 41
    - 29
    - 22
    - 17
    - 12
    - 11

**Follow up (year)**: 0, 1, 2, 3, 4, 5
Figure Legend

**Figure 1** Study flowchart

**Figure 2** Kaplan-Meier survivorship curve for entire cohort versus controls with treatment failure as an endpoint.

**Figure 3** Kaplan-Meier survivorship curve for subgroup of cohort who underwent spacer exchange only for infection (i.e. not for dislocation or other non-infection reasons) versus all controls with treatment failure as an endpoint.

**Figure 4** Kaplan-Meier survivorship curve for entire cohort versus controls for two-stage exchange arthroplasty after THA PJI with treatment failure as an endpoint.

**Figure 5** Kaplan-Meier survivorship curve for entire cohort versus controls for two-stage exchange arthroplasty after THA PJI with treatment failure as an endpoint.

**Appendix Figure 1** Kaplan-Meier implant survivorship curve for entire cohort versus controls after matching.

**Appendix Figure 2** Kaplan-Meier implant survivorship curve for subgroup of cohort who underwent spacer exchange only for infection (i.e. not for dislocation or other non-infection reasons) versus controls after matching.